Niven R. Narain is co-founder, president, and chief technology officer of Berg Pharma, which focuses its research on understanding how alterations in metabolism relate to disease onset. His passion is innovation that drives patient care and the generation of actionable biological data. He discovered BPM 31510, the novel cancer drug in late stage clinical development for skin cancers and solid tumors. Most notably, Narain developed the Interrogative Biology platform, which uses core biological modeling to develop safe, effective drugs in a cost-effective manner. He has over 160 issued and pending patents and was director of cutaneous oncology at the University of Miami Miller School of Medicine. Narain is committed to changing the paradigm of innovation in medicine. @bergpharma